-
Mapping Pseudouridine on mRNA: Antibody-Based PA-Ψ-seq Insig
2026-05-07
This study introduces PA-Ψ-seq, a novel antibody-based technique for mapping pseudouridine (Ψ) residues on cellular and viral transcripts. The findings clarify the distribution and enzyme dependencies of Ψ in human and HIV-1 RNAs, with implications for understanding immune evasion and mRNA function.
-
Toremifene: Optimizing Selective Estrogen-Receptor Modulator
2026-05-06
Toremifene, a second-generation selective estrogen-receptor modulator, is redefining prostate cancer research by enabling precise modulation of estrogen signaling and cell growth inhibition. Discover best practices, protocol enhancements, and troubleshooting strategies for leveraging Toremifene in advanced hormone-responsive cancer models.
-
VX-765: Selective Caspase-1 Inhibitor for Pyroptosis Researc
2026-05-06
VX-765 is a potent, orally absorbed caspase-1 inhibitor that selectively suppresses IL-1β and IL-18 release. Its utility spans inflammation, pyroptosis, and translational disease models, with robust evidence for cell-protective effects. APExBIO’s VX-765 (A8238) is validated in both biochemical and cellular assays.
-
Berberine Hydrochloride: Advanced Workflows in Metabolic Dis
2026-05-05
Unlock the full translational power of Berberine Hydrochloride in metabolic, inflammation, and cancer research with proven protocols and troubleshooting guidance. APExBIO’s high-purity Berberine Hydrochloride (SKU N1368) enables reproducible LDLR upregulation, AMPK activation, and robust lipid modulation in both cell-based and animal models.
-
Haloprogin: Broad-Spectrum Antifungal for Research Workflows
2026-05-05
Haloprogin (1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene) powers next-generation antifungal and antimicrobial research with low MICs against dermatophytes, yeasts, and Gram-positive bacteria. This article translates foundational studies and modern protocols into actionable guidance for reproducible in vitro and in vivo experimentation.
-
Peptide Affinity Tags for Imaging P. aeruginosa Lytic Phages
2026-05-04
This study introduces a novel peptide that specifically binds to a lytic bacteriophage infecting Pseudomonas aeruginosa, enabling direct fluorescent labeling and tracking. The findings address a critical gap in phage therapy research, offering new tools for monitoring phage distribution and efficacy in the context of escalating antimicrobial resistance.
-
Dextrose (D-glucose): Precision Workflows for Glucose Metabo
2026-05-04
Dextrose (D-glucose) empowers metabolic and immunometabolic research with unmatched purity, solubility, and protocol adaptability. This guide details workflow optimizations, troubleshooting, and advanced applications for deciphering glucose-driven cellular dynamics in oncology and diabetes research.
-
(S)-Mephenytoin as a CYP2C19 Substrate in Organoid Metabolis
2026-05-03
(S)-Mephenytoin is the gold-standard CYP2C19 substrate, enabling precise evaluation of cytochrome P450 metabolism in hiPSC-derived intestinal organoid models. This article details experimental workflows, troubleshooting guidance, and how recent innovations in organoid protocols maximize the translational value of (S)-Mephenytoin for pharmacokinetic research.
-
NMDA Agonism: Precision Tools for Excitotoxicity & Neuroprot
2026-05-02
This article explores the mechanistic underpinnings and translational relevance of NMDA (N-Methyl-D-aspartic acid) as a research tool for modeling excitotoxicity, oxidative stress, and ferroptosis in neurodegenerative disease models. We integrate evidence from recent studies—including glaucoma research leveraging NMDA-induced injury—and offer strategic protocol guidance for translational researchers. The discussion highlights product differentiation, experimental rigor, and future directions for NMDA-based workflow optimization.
-
mRNA-LNP Tailored CAR Macrophages for Peritoneal Tumor Immun
2026-05-01
This study introduces a macrophage-specific mRNA lipid nanoparticle (mRNA-LNP) system for in situ programming of chimeric antigen receptor macrophages (CAR-Ms) to address peritoneal metastasis in solid tumors. The approach systematically evaluates CAR intracellular domains, identifies formats with potent immune activation, and demonstrates synergy with checkpoint blockade—providing a new translational avenue for cancer immunotherapy.
-
Patient-Derived 3D Spheroid Models Advance Prostate Cancer R
2026-05-01
This article examines a recent study demonstrating the development and validation of patient-derived three-dimensional (3D) spheroid cultures as translational models for organ-confined prostate cancer. The work provides a critical foundation for more physiologically relevant preclinical testing, including insights on androgen pathway targeting.
-
NMDA (N-Methyl-D-aspartic acid): Precision Tools for Excitot
2026-04-30
NMDA (N-Methyl-D-aspartic acid) from APExBIO empowers neuroscience researchers to model excitotoxicity, oxidative stress, and neurodegenerative disease mechanisms with high reproducibility. This guide details optimized workflows, troubleshooting strategies, and data-driven parameters for leveraging NMDA in applied research, with insights from the latest stem cell and glaucoma studies.
-
Red Blood Cell Lysis Buffer: Precision Tools for Modern Hema
2026-04-30
Discover how Red Blood Cell Lysis Buffer enables precise erythrocyte removal and advanced blood sample preparation. Explore unique scientific insights and practical protocol strategies for flow cytometry, nucleic acid, and protein extraction.
-
Evaluating Anti-Cancer Drug Responses: Insights from In Vitr
2026-04-29
Schwartz's dissertation critically redefines how in vitro drug responses are measured, highlighting the divergent roles of proliferation arrest and cell death in evaluating anti-cancer efficacy. This nuanced approach offers researchers enhanced precision in characterizing mechanisms of topoisomerase 1 inhibitors and other agents, informing both experimental design and translational applications.
-
Dual PI3K–AKT–ERK Blockade Overcomes Gefitinib Resistance in
2026-04-29
Deng et al. present a rationally designed nanoplatform for the co-delivery of gefitinib and crizotinib, targeting PI3K–AKT–ERK signaling to overcome resistance and metastasis in lung adenocarcinoma. Their integrated approach demonstrates the potential of dual-pathway inhibition to address key therapeutic challenges in non-small cell lung cancer.